top of page

Boston Patent Law Association Honors General Oncology’s Founder for Invention of Novel Investigational Chemotherapy

November 15, 2022

The treatment given to the founder’s sister, who is now 10 years cancer-free, has led to a clinical trial at major medical centers.

BOSTON— General Oncology, Inc. today announced that on November 9, 2022, the Boston Patent Law Association (BPLA) honored Arnold Glazier, M.D., founder and Chief Science and Medical Officer of General Oncology, at the BPLA’s 12th annual Invented Here! event. Dr. Glazier received the honor for his role as inventor of U.S. patent 11,154,520, “Combination Therapy for Metastatic Cancer,” which was granted on August 31, 2021. According to the BPLA website, “The purpose of the Invented Here! Program is to celebrate New England innovators, their inventions, and the stories behind their innovations.”

The patent relates to the investigational treatment that is being used in the company’s ongoing clinical trial at leading hospitals in Boston and New York. The identifier for the trial is NCT04150042 and the listing is found at


“My invention is a new approach for the treatment of metastatic cancer,” said Dr. Glazier during his acceptance speech. “In 2012, my sister Sharon was diagnosed with pancreatic cancer in the setting of an inherited BRCA mutation. With conventional therapy, her prognosis was grim. Pancreatic cancer is one of the deadliest cancers. Sharon asked me to invent a new treatment for her that would (1) offer a real chance for cure and (2) not cause her any chronic side effects. My sister, who is a physician, said I needed to accomplish this seemingly impossible task within six weeks. Today, Sharon is more than 10 years cancer-free. She is here with me tonight. The present invention is a refinement of the treatment I developed for Sharon. The treatment uses four drugs, followed by an infusion of a patient’s bone marrow stem cells. There is currently a clinical trial using this invention at top hospitals in Boston and New York. My hope is that it will benefit patients and improve lives.”

A video of Dr. Glazier’s speech can be found at

About General Oncology, Inc.

General Oncology is a pharmaceutical company dedicated to developing highly effective and safe treatments for metastatic cancers.  In addition to the investigational treatment in the SHARON Trial, the company has a pipeline of drug candidates for other solid tumors, as well as for myeloma, lymphoma, and leukemia. For more information about General Oncology, please visit



Jeff Glazier

(617) 468-4646

bottom of page